4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy that uses adeno-associated virus vectors to develop product candidates in three therapeutic areas: ophthalmology, cardiology, and pulmonology. 4D Molecular Therapeutics has research and collaboration arrangements with uniQure, CRF, Roche, and CFF. The company was founded in 2013 and is headquartered in Emeryville, CA.
Name / Ticker | Price | Zen Rating |
---|---|---|
$7.59 | A | |
$3.58 | A | |
$46.15 | A |